Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.75 +0.02 (+0.23%)
As of: Aug 21, 2026 · 2:31 PM EDT

Drugs Made In America Acquisition (DMAA) Long-Term Debt Issuances (2025)

Drugs Made In America Acquisition's (DMAA) quarterly Long-Term Debt Issuances came in at $900000.0 in Q1 2025.

Drugs Made In America Acquisition (DMAA) Long-Term Debt Issuances (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of Long-Term Debt Issuances data on file, last reported at $900000.0 in Q1 2025.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $900000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $900000.0 (changed N/A YoY) and the FY2025 annual result came in at $900000.0, down 30.79% from the prior year.
  • Long-Term Debt Issuances steadied at $900000.0 in Q1 2025.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $900000.0 in Q1 2025 to a low of $900000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - -
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -
6 Aldel Financial 397.49 Mn 397.49 Mn - -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -
8 Gores Holdings X 385.06 Mn 384.87 Mn - -
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - -
10 Drugs Made In America Acquisition 215.82 Mn 215.82 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 900,000.00
Mar 31, 2025 900,000.00